TRK-950 is under clinical development by Toray Industries and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TRK-950’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TRK-950 overview

TRK-950 is under development for the treatment of metastatic cholangiocarcinoma, metastatic gastric cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, gastroesophageal junction cancer, melanoma, epithelial ovarian, primary peritoneal or fallopian tube cancer and metastatic bladder cancer. The drug candidate is administered through intravenous route. It is a monoclonal antibody that acts by targeting CAPRIN-1.

It was also under development for the treatment for hepatomas, advanced or metastatic solid carcinomas and colon cancer.

Toray Industries overview

Toray Industries (Toray) is a provider of advanced materials. The company’s product portfolio includes fibers, fashion apparel, plastics, chemicals, composite materials, life sciences products, and medical devices, pharmaceuticals, and optical products. It also provides carbon fibers, carbon fiber composite materials, polyester, polyethylene, polypropylene and water treatment membranes. Its products are used in apparel, industrial materials, automotive, construction, water treatment and medical industries. It also provides physical evaluation, analysis, and research-related services. Toray also provides comprehensive engineering, condominiums, industrial equipment and machinery, IT-related equipment, water treatment membranes and related equipment, and materials for housing, building and civil engineering applications. The company operates in various countries in Asia Pacific, North America, South America and Europe. Toray is headquartered in Tokyo, Japan.

For a complete picture of TRK-950’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.